Literature DB >> 28857297

Cost-of-illness of psoriasis - results of a German cross-sectional study.

D Jungen1, M Augustin1, A Langenbruch1, N Zander1, K Reich2, K Strömer3, D Thaci4, S Purwins1, M Radtke1, M Gutknecht1.   

Abstract

BACKGROUND: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany.
OBJECTIVES: The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective.
METHODS: A cross-sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness-related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non-parametric tests.
RESULTS: Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out-of-pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+-year-old patients were found.
CONCLUSIONS: Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out-of-pocket and indirect costs towards systemic drug costs.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2017        PMID: 28857297     DOI: 10.1111/jdv.14543

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

Review 1.  [Regional variations in healthcare for patients with psoriasis and atopic dermatitis in Germany].

Authors:  M Augustin; C Garbe; S Neitemeier; T Steimle; S Schwarz; J Augustin; R von Kiedrowski; K Hagenström
Journal:  Hautarzt       Date:  2021-11-25       Impact factor: 0.751

2.  Improving management of psoriasis patients receiving biological treatment: A qualitative approach.

Authors:  Bettina Trettin; Steven Feldman; Flemming Andersen; Dorthe B Danbjørg; Hanne Agerskov
Journal:  Nurs Open       Date:  2021-01-01

3.  The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

Authors:  Ahmed H Seddik; Nima Melzer; Foteini Tsotra; Dennis A Ostwald
Journal:  Pharmacoecon Open       Date:  2021-10-19

Review 4.  Economic Burden of Chronic Hand Eczema: A Review.

Authors:  April Armstrong; Julie Hahn-Pedersen; Chris Bartlett; Julie Glanville; Jacob P Thyssen
Journal:  Am J Clin Dermatol       Date:  2022-03-08       Impact factor: 6.233

5.  Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature.

Authors:  Andreas Pinter; Henrik Thormann; Flavia Angeletti; Ahmad Jalili
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-10-09

6.  Medical resource consumption of moderate/severe psoriasis in a private health organization of Buenos Aires, Argentina.

Authors:  María Laura Galimberti; Aldana S Vacas; Barbara A Hernández; María L Bollea Garlatti; María J Cura; Ricardo L Galimberti
Journal:  An Bras Dermatol       Date:  2019-12-06       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.